Central Alerting System
View Alert


Originator: CMO Messaging

From: CMO Messaging

Issue date: 12-Apr-2021 15:02:36

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: COVID-19 Therapeutic Alert - Inhaled Budesonide for Adults (50 Years and Over) with COVID-19

Broadcast content: The recent announcement of the interim results from the National Institute for Health Research (NIHR) supported PRINCIPLE trial shows that inhaled budesonide (typically used and licensed in the management of asthma) can reduce the recovery time for COVID-19 positive patients being managed within primary care. This is the first COVID-19 treatment for use in the UK within a community setting.
*** Please note that an update to this alert was issued on 14 December 2021: https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103185 ***


Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy.

Alert reference: CEM/CMO/2021/011

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency